Published in Ann Fam Med on September 25, 2007
Baseline characteristics of African Americans in the Systolic Blood Pressure Intervention Trial. J Am Soc Hypertens (2015) 2.11
Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States. Dig Dis Sci (2009) 1.17
Proximal tumors are associated with greater mortality in colon cancer. J Gen Intern Med (2010) 0.97
Epidemiology and management of hypertension in the Hispanic population: a review of the available literature. Am J Cardiovasc Drugs (2012) 0.82
A review of the efficacy and tolerability of combination amlodipine/valsartan in non-white patients with hypertension. Am J Cardiovasc Drugs (2013) 0.77
Does race affect a patient's response to antihypertensives? J Fam Pract (2007) 0.75
Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity. Intern Emerg Med (2016) 0.75
The need for multicentre cardiovascular clinical trials in Asia. Nat Rev Cardiol (2013) 0.75
Valsartan combination therapy in the management of hypertension - patient perspectives and clinical utility. Integr Blood Press Control (2009) 0.75
Ethics and Community Involvement in Syntheses Concerning American Indian, Alaska Native, or Native Hawaiian Health: A Systematic Review. AJOB Empir Bioeth (2014) 0.75
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet (2001) 17.97
Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA (2003) 14.77
Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 14.72
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA (2002) 12.29
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 11.13
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med (2003) 7.74
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA (2003) 7.42
Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA (1993) 6.27
Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens (1996) 4.66
Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet (2004) 4.51
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med (2003) 4.08
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA (2005) 3.89
Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group. Lancet (1997) 3.76
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA (2003) 3.71
Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens (2003) 3.67
Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care (1998) 3.52
The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens (2005) 3.27
Adequacy of reporting race/ethnicity in clinical trials in areas of health disparities. J Clin Epidemiol (2003) 2.94
Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol (1998) 2.62
Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension (2003) 1.85
Comparison of reporting of ethnicity in US and European randomised controlled trials. BMJ (2004) 1.85
Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens (2003) 1.74
Disparities in premature deaths from heart disease--50 States and the District of Columbia, 2001. MMWR Morb Mortal Wkly Rep (2004) 1.74
Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit (2005) 1.70
The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol (2001) 1.68
Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy. J Am Coll Cardiol (2002) 1.50
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens (1997) 1.28
Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients--findings from the International Verapamil SR/Trandolapril Study (INVEST). Am Heart J (2006) 1.17
Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Hypertension (1999) 1.04
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol (2004) 0.99
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension (1998) 0.99
Update on disparities in the pathophysiology and management of hypertension: focus on African Americans. Med Clin North Am (2005) 0.99
Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res (2004) 0.98
Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. J Hypertens (2006) 0.94
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press (1998) 0.92
Treatment of isolated systolic hypertension: the SHELL study results. Blood Press (2003) 0.92
Five-year findings of the Hypertension Detection and Follow-up Program: mortality by race-sex and blood pressure level. A further analysis. Hypertension Detection and Follow-up Program Cooperative Group. J Community Health (1984) 0.87
Perindopril-based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. J Hypertens (2004) 0.79
Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) analyses performed up to 1992. Clin Exp Hypertens (1993) 0.79
Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. Blood Press (2001) 0.78
[Treatment of elderly hypertension based on various hypertension management guidelines--comparison between European and American guidelines and Japanese guidelines]. Nihon Rinsho (2005) 0.77
The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens (2003) 0.77
PROGRESS (Perindopril Protection Against Recurrent Stroke Study): regional characteristics of the study population at baseline. PROGRESS Management Committee. J Hypertens Suppl (2000) 0.77
Evidence-based guidelines for cardiovascular disease prevention in women. Circulation (2004) 3.39
Organizational climate and family life: how these factors affect the status of women faculty at one medical school. Acad Med (2009) 1.64
Evidence-based guidelines for cardiovascular disease prevention in women. J Am Coll Cardiol (2004) 1.59
Screening for early detection of cardiovascular disease in asymptomatic individuals. Am Heart J (2003) 1.58
Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol (2006) 1.54
Evidence-based guidelines for cardiovascular disease prevention in women. American Heart Association scientific statement. Arterioscler Thromb Vasc Biol (2004) 1.49
Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. Am J Hypertens (2002) 1.21
African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail (2002) 1.11
Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial. J Am Coll Cardiol (2006) 1.03
Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. J Card Fail (2007) 0.97
Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial. J Card Fail (2008) 0.94
Outcomes of comprehensive heart care programs in high-risk women. J Womens Health (Larchmt) (2010) 0.88
The DHHS Office on Women's Health Initiative to Improve Women's Heart Health: focus on knowledge and awareness among women with cardiometabolic risk factors. J Womens Health (Larchmt) (2011) 0.84
Relating mentor type and mentoring behaviors to academic medicine faculty satisfaction and productivity at one medical school. Acad Med (2014) 0.84
New recommendations for treating hypertension in black patients: evidence and/or consensus? Hypertension (2010) 0.83
Summary of the American Heart Association's evidence-based guidelines for cardiovascular disease prevention in women. Arterioscler Thromb Vasc Biol (2004) 0.81
HFSA and AAHFN joint position statement: advocating for a full scope of nursing practice and leadership in heart failure. J Card Fail (2012) 0.78
Race-related differences in heart failure therapies: simply black and white or shades of grey? Curr Cardiol Rep (2007) 0.78
Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial. Am J Cardiovasc Drugs (2007) 0.76
The Office on Women's Health initiative to improve women's heart health: program description, site characteristics, and lessons learned. J Womens Health (Larchmt) (2010) 0.76
Letter by Taylor et al regarding article, "Hydralazine and isosorbide dinitrate in heart failure: historical perspectives, mechanisms, and future directions". Circulation (2011) 0.75
HFSA and AAHFN joint position statement: advocating for a full scope of nursing practice and leadership in heart failure. Heart Lung (2012) 0.75
Atrial fibrillation and mortality in African American patients with heart failure: results from the African American Heart Failure Trial (A-HeFT). Am Heart J (2011) 0.75
Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial. J Card Fail (2008) 0.75
Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure. Cleve Clin J Med (2007) 0.75